Barbara Schmalfeldt
Papers
3
Total Citations
131
H-Index
3
About
Barbara Schmalfeldt is a prominent gynecological oncologist whose research has made significant contributions to the understanding and clinical management of borderline ovarian tumors (BOT). Her work, conducted in collaboration with the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO), has been instrumental in refining treatment protocols and prognostic frameworks for this complex category of ovarian neoplasm. Through her leadership in the AGO ROBOT study — a large-scale, multi-institutional investigation — Schmalfeldt and her colleagues analyzed data from nearly 1,000 patients, revealing critical insights into how age influences clinical presentation and outcomes, and how the completeness of surgical staging serves as a meaningful prognostic factor. Her most-cited work (75 citations) highlighted age-dependent differences in BOT, while subsequent analyses further clarified the value of individual staging procedures in predicting recurrence and survival. Schmalfeldt has also advanced diagnostic practice by investigating the role of serum CA125 as a biomarker in BOT identification. Collectively, her research has shaped evidence-based guidelines in gynecologic oncology and continues to inform clinicians managing patients with borderline ovarian disease worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary14 citations · 2015